Literature DB >> 21921063

Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.

Anna S C Conlon1, Jeremy M G Taylor, Daniel J Sargent, Greg Yothers.   

Abstract

BACKGROUND: Intermediate outcome variables can often be used as auxiliary variables for the true outcome of interest in randomized clinical trials. For many cancers, time to recurrence is an informative marker in predicting a patient's overall survival outcome and could provide auxiliary information for the analysis of survival times.
PURPOSE: To investigate whether models linking recurrence and death combined with a multiple imputation procedure for censored observations can result in efficiency gains in the estimation of treatment effects and be used to shorten trial lengths.
METHODS: Recurrence and death times are modeled using data from 12 trials in colorectal cancer. Multiple imputation is used as a strategy for handling missing values arising from censoring. The imputation procedure uses a cure model for time to recurrence and a time-dependent Weibull proportional hazards model for time to death. Recurrence times are imputed, and then death times are imputed conditionally on recurrence times. To illustrate these methods, trials are artificially censored 2 years after the last accrual, the imputation procedure implemented, and a log-rank test and Cox model used to analyze and compare these new data with the original data.
RESULTS: The results show modest, but consistent gains in efficiency in the analysis using the auxiliary information in recurrence times. Comparison of analyses show the treatment effect estimates and log-rank test results from the 2-year censored imputed data to be in between the estimates from the original data and the artificially censored data, indicating that the procedure was able to recover some of the lost information due to censoring. LIMITATIONS: The models used are all fully parametric, requiring distributional assumptions of the data.
CONCLUSIONS: The proposed models may be useful in improving the efficiency in estimation of treatment effects in cancer trials and shortening trial length.

Entities:  

Mesh:

Year:  2011        PMID: 21921063      PMCID: PMC3197975          DOI: 10.1177/1740774511414741

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  16 in total

1.  Survival analysis using auxiliary variables via non-parametric multiple imputation.

Authors:  Chiu-Hsieh Hsu; Jeremy M G Taylor; Susan Murray; Daniel Commenges
Journal:  Stat Med       Date:  2006-10-30       Impact factor: 2.373

2.  Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective.

Authors:  Ariel Alonso; Geert Molenberghs
Journal:  Stat Methods Med Res       Date:  2008-02-19       Impact factor: 3.021

3.  Long-term survivor model with bivariate random effects: applications to bone marrow transplant and carcinoma study data.

Authors:  Xin Lai; Kelvin K W Yau
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

4.  Statistical validation of intermediate endpoints for chronic diseases.

Authors:  L S Freedman; B I Graubard; A Schatzkin
Journal:  Stat Med       Date:  1992-01-30       Impact factor: 2.373

5.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

6.  Criteria for the validation of surrogate endpoints in randomized experiments.

Authors:  M Buyse; G Molenberghs
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

7.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.

Authors:  T R Fleming; R L Prentice; M S Pepe; D Glidden
Journal:  Stat Med       Date:  1994-05-15       Impact factor: 2.373

8.  Mixture cure model with random effects for the analysis of a multi-center tonsil cancer study.

Authors:  Yingwei Peng; Jeremy M G Taylor
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

9.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

10.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

View more
  4 in total

1.  A model-informed rank test for right-censored data with intermediate states.

Authors:  Ritesh Ramchandani; Dianne M Finkelstein; David A Schoenfeld
Journal:  Stat Med       Date:  2015-01-13       Impact factor: 2.373

2.  Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.

Authors:  A S C Conlon; J M G Taylor; D J Sargent
Journal:  Biometrics       Date:  2015-01-13       Impact factor: 2.571

3.  Multi-state models for colon cancer recurrence and death with a cured fraction.

Authors:  A S C Conlon; J M G Taylor; D J Sargent
Journal:  Stat Med       Date:  2013-12-05       Impact factor: 2.373

4.  Joint modelling of colorectal cancer recurrence and death after resection using multi-state model with cured fraction.

Authors:  Behnaz Alafchi; Ghodratollah Roshanaei; Leili Tapak; Mohammad Abbasi; Hossein Mahjub
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.